• KOL
    • Ev71 Vaccine
    • Immunogenicity And Safety...
    • Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-: Influence Statistics

      Expert Impact

      Concepts for whichthey havehas direct influence:Ev71 vaccine,Ev71 vaccine day,Simultaneous administration,Inactivated enterovirus,Immunogenicity safety,71 vaccine,Enterovirus 71,Safety simultaneous administration.

      Key People For Ev71 Vaccine

      Top KOLs in the world
      #1
      Jun‐Zhi Wang
      neutralizing antibodies japanese encephalitis reporter gene
      #2
      Zheng‐Lun Liang
      neutralizing antibodies ev71 vaccine mouth disease
      #3
      Qun‐Ying Mao
      neutralizing antibodies mouth disease ev71 vaccine
      #4
      Jen‐Ren Wang
      influenza virus southern taiwan viral replication
      #5
      Peter Charles McMinn
      human enterovirus murray valley encephalitis western australia
      #6
      Xin Yao
      neutralizing antibodies mouth disease analytical sensitivity

      Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-

      Abstract

      BACKGROUND: This study tested the hypothesis that the immunogenicity and safety of the simultaneous administration of enterovirus 71 (EV71) vaccine (dose 1) with recombinant hepatitis B vaccine (HepB) on day 1 and EV71 vaccine (dose 2) with group A meningococcal polysaccharide vaccine (MenA) on day 30 is not inferior to separate administration of each vaccine.

      METHODS: The study was designed as a randomized, open-label, noninferiority trial. A total of 775 healthy infants aged 6 months were randomly assigned in a ratio of 1:1:1 to receive simultaneous administration of EV71 vaccine (dose 1) and HepB on day 1 and EV71 vaccine (dose 2) and MenA on day 30 (the SI group); administration of doses 1 and 2 of EV71 vaccine on days 1 and 30, respectively (the SE1 group); or administration of HepB and MenA on days 1 and 30, respectively (the SE2 group).

      RESULTS: According to the per protocol set, antibody responses against EV71, hepatitis B virus (HBV), and group A meningococcal polysaccharide were similar regardless of administration schedule. With the non-inferiority margin setting at 10%, the seroconversion rates of the three pathogens in the SI group (100% [98.25, 100], 44.84% [38.20, 51.63] and 27.83% [21.91, 34.38]) were not inferior to those in SE1 or SE2 group (100% [98.31, 100], 44.35% [37.82, 51.02] and 29.17% [23.20, 35.72], respectively). Frequencies of adverse reactions to each vaccination regimen were comparable (60.62% in the SI group vs 52.33% in the SE1 group and 56.98% in the SE2 group; P = .16).

      CONCLUSIONS: Simultaneous administration of combined EV71 vaccine with HepB and MenA has noninferior immunogenicity and safety, compared with separate administration of these vaccines.

      CLINICAL TRIALS REGISTRATION: NCT03274102.

      Sign-in to see all concepts, it's free!

       

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.